Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Lorlatinib | hsa00030 | Pentose phosphate pathway | 1.94E-03 | 2 | P52209, P37837 | PGD, TALDO1 | More | | Lorlatinib | hsa00270 | Cysteine and methionine metabolism | 1.92E-02 | 2 | Q96RQ9, P40926 | IL4I1, MDH2 | More | | Lorlatinib | hsa00310 | Lysine degradation | 2.59E-02 | 2 | Q96KQ7, P51648 | EHMT2, ALDH3A2 | More | | Lorlatinib | hsa00500 | Starch and sucrose metabolism | 2.67E-02 | 1 | P35573 | AGL | More | | Lorlatinib | hsa00510 | N-Glycan biosynthesis | 3.15E-02 | 2 | P15907, Q9NR34 | ST6GAL1, MAN1C1 | More | | Lorlatinib | hsa00512 | Mucin type O-glycan biosynthesis | 4.86E-02 | 2 | O95395, Q9NY28 | GCNT3, GALNT8 | More | | Lorlatinib | hsa00590 | Arachidonic acid metabolism | 2.48E-03 | 3 | P11712, P09917, P09960 | CYP2C9, ALOX5, LTA4H | More | | Lorlatinib | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Lorlatinib | hsa00600 | Sphingolipid metabolism | 2.44E-02 | 2 | Q9BX95, Q06136 | SGPP1, FVT1 | More | | Lorlatinib | hsa00630 | Glyoxylate and dicarboxylate metabolism | 9.62E-04 | 3 | P40925, P40926, P15104 | MDH1, MDH2, GLUL | More | | Lorlatinib | hsa00750 | Vitamin B6 metabolism | 4.45E-02 | 1 | O00764 | PDXK | More | | Lorlatinib | hsa00770 | Pantothenate and CoA biosynthesis | 1.94E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | Lorlatinib | hsa00785 | Lipoic acid metabolism | 4.32E-02 | 1 | Q9Y234 | LIPT1 | More | | Lorlatinib | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Lorlatinib | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Lorlatinib | hsa01040 | Biosynthesis of unsaturated fatty acids | 4.28E-02 | 1 | P22307 | SCP2 | More | | Lorlatinib | hsa01200 | Carbon metabolism | 2.13E-02 | 2 | P52209, P37837 | PGD, TALDO1 | More | | Lorlatinib | hsa01524 | Platinum drug resistance | 4.94E-02 | 2 | P78417, P52701 | GSTO1, MSH6 | More | | Lorlatinib | hsa03013 | RNA transport | 3.52E-02 | 4 | P52298, O14893, O14602, P78345 | NCBP2, GEMIN2, EIF1AY, RPP38 | More | | Lorlatinib | hsa03022 | Basal transcription factors | 3.52E-03 | 3 | O00268, Q5H9L4, Q15544 | TAF4, TAF7L, TAF11 | More | | Lorlatinib | hsa03040 | Spliceosome | 4.48E-04 | 10 | Q14562, O43143, O60508, P17844, P51991, P61978, Q07955, Q01130, Q13243, P11142 | DHX8, DHX15, CDC40, DDX5, HNRPA3, HNRPK, SFRS1, SFRS2, SFRS5, HSPA8 | More | | Lorlatinib | hsa03050 | Proteasome | 4.83E-02 | 1 | P55036 | PSMD4 | More | | Lorlatinib | hsa03320 | PPAR signaling pathway | 4.33E-02 | 2 | Q6PCB7, Q9UNU6 | SLC27A1, CYP8B1 | More | | Lorlatinib | hsa03450 | Non-homologous end-joining | 4.32E-02 | 1 | Q9NP87 | POLM | More | | Lorlatinib | hsa04010 | MAPK signaling pathway | 4.76E-02 | 5 | Q15283, P21860, Q12933, P01584, O14944 | RASA2, ERBB3, TRAF2, IL1B, EREG | More | | Lorlatinib | hsa04014 | Ras signaling pathway | 8.66E-03 | 7 | Q9NRA1, Q13009, P0DP23, P62873, P63218, P50151, P19174 | PDGFC, TIAM1, CALM1, GNB1, GNG5, GNG10, PLCG1 | More | | Lorlatinib | hsa04020 | Calcium signaling pathway | 1.43E-03 | 7 | Q96DU7, Q08828, P21796, Q13557, P21860, P30679, P23634 | ITPKC, ADCY1, VDAC1, CAMK2D, ERBB3, GNA15, ATP2B4 | More | | Lorlatinib | hsa04062 | Chemokine signaling pathway | 1.59E-03 | 9 | P07948, P19174, P62873, P63218, P50151, Q13009, P14598, P42224, P25963 | LYN, PLCG1, GNB1, GNG5, GNG10, TIAM1, NCF1, STAT1, NFKBIA | More | | Lorlatinib | hsa04064 | NF-kappa B signaling pathway | 2.98E-04 | 12 | P10415, O00463, Q13546, P01375, Q04759, Q9UDY8, Q13077, Q16548, P06239, Q13315, P24522, P09341 | BCL2, TRAF5, RIPK1, TNF, PRKCQ, MALT1, TRAF1, BCL2A1, LCK, ATM, GADD45A, CXCL1 | More | | Lorlatinib | hsa04070 | Phosphatidylinositol signaling system | 2.37E-03 | 6 | P19174, P0DP23, P23743, Q86XP1, P27987, Q96DU7 | PLCG1, CALM1, DGKA, DGKH, ITPKB, ITPKC | More | | Lorlatinib | hsa04114 | Oocyte meiosis | 6.23E-03 | 5 | Q9Y6D9, P51812, Q02750, P16298, Q17RY0 | MAD1L1, RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | Lorlatinib | hsa04115 | p53 signaling pathway | 2.54E-02 | 3 | O15151, Q13315, P10415 | MDM4, ATM, BCL2 | More | | Lorlatinib | hsa04140 | Autophagy - animal | 4.55E-02 | 5 | P22694, Q14643, P10415, Q9H1Y0, Q04759 | PRKACB, ITPR1, BCL2, ATG5, PRKCQ | More | | Lorlatinib | hsa04141 | Protein processing in endoplasmic reticulum | 1.22E-04 | 11 | P18848, P30101, Q15437, P60604, Q99941, P11142, P07900, P08238, Q9NR31, Q9H173, Q9UNL2 | ATF4, PDIA3, SEC23B, UBE2G2, CREBL1, HSPA8, HSP90AA1, HSP90AB1, SAR1A, SIL1, SSR3 | More | | Lorlatinib | hsa04145 | Phagosome | 1.72E-04 | 13 | O75015, P11215, Q15080, P14598, Q71U36, Q13509, P68371, Q13488, P05164, P78380, O60603, P35443, P13765 | FCGR3B, ITGAM, NCF4, NCF1, TUBA1A, TUBB3, TUBB2C, TCIRG1, MPO, OLR1, TLR2, THBS4, HLA-DOB | More | | Lorlatinib | hsa04151 | PI3K-Akt signaling pathway | 3.91E-03 | 7 | P62753, P27348, P07900, P22105, Q99941, P18848, O00141 | RPS6, YWHAQ, HSP90AA1, TNXB, CREBL1, ATF4, SGK | More | | Lorlatinib | hsa04211 | Longevity regulating pathway | 2.72E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | | Lorlatinib | hsa04217 | Necroptosis | 1.93E-02 | 4 | P01568, Q13489, Q13546, Q6FI13 | IFNA21, BIRC3, RIPK1, H2AC18; H2AC19 | More | | Lorlatinib | hsa04261 | Adrenergic signaling in cardiomyocytes | 1.46E-02 | 4 | P51828, Q99941, P18848, Q13557 | ADCY7, CREBL1, ATF4, CAMK2D | More | | Lorlatinib | hsa04270 | Vascular smooth muscle contraction | 2.89E-02 | 2 | P35579, P35318 | MYH9, ADM | More | | Lorlatinib | hsa04310 | Wnt signaling pathway | 5.60E-03 | 3 | P30279, Q13485, O43318 | CCND2, SMAD4, MAP3K7 | More | | Lorlatinib | hsa04370 | VEGF signaling pathway | 3.06E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | Lorlatinib | hsa04371 | Apelin signaling pathway | 7.95E-04 | 7 | P62873, P63218, P50151, Q13370, Q14344, P84022, P0DP23 | GNB1, GNG5, GNG10, PDE3B, GNA13, SMAD3, CALM1 | More | | Lorlatinib | hsa04390 | Hippo signaling pathway | 5.79E-03 | 4 | P04628, Q9UJU2, O43623, Q13489 | WNT1, LEF1, SNAI2, BIRC3 | More | | Lorlatinib | hsa04520 | Adherens junction | 3.91E-02 | 2 | Q13485, O43318 | SMAD4, MAP3K7 | More | | Lorlatinib | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Lorlatinib | hsa04540 | Gap junction | 2.59E-04 | 4 | Q13509, P68371, Q71U36, Q9NRA1 | TUBB3, TUBB2C, TUBA1A, PDGFC | More | | Lorlatinib | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 4.73E-02 | 3 | Q13873, Q02750, Q86SE9 | BMPR2, MAP2K1, PCGF5 | More | | Lorlatinib | hsa04612 | Antigen processing and presentation | 3.69E-02 | 7 | P13765, P48382, P26715, P26717, Q13241, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | Lorlatinib | hsa04613 | Neutrophil extracellular trap formation | 1.73E-02 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Lorlatinib | hsa04623 | Cytosolic DNA-sensing pathway | 3.04E-04 | 3 | P01568, Q13546, P25963 | IFNA21, RIPK1, NFKBIA | More | | Lorlatinib | hsa04640 | Hematopoietic cell lineage | 4.72E-02 | 8 | P13612, P27930, P15144, P25063, P09693, P01732, P13765, P01375 | ITGA4, IL1R2, ANPEP, CD24, CD3G, CD8A, HLA-DOB, TNF | More | | Lorlatinib | hsa04650 | Natural killer cell mediated cytotoxicity | 7.47E-04 | 12 | P16298, P50591, P01375, P06239, O60880, P20963, Q02750, Q13241, P26718, O75015, P26717, P26715 | PPP3CB, TNFSF10, TNF, LCK, SH2D1A, CD247, MAP2K1, KLRD1, KLRK1, FCGR3B, KLRC2, KLRC1 | More | | Lorlatinib | hsa04658 | Th1 and Th2 cell differentiation | 4.78E-03 | 8 | Q04759, P20963, P09693, P06239, Q14765, P23771, Q9UL17, P13765 | PRKCQ, CD247, CD3G, LCK, STAT4, GATA3, TBX21, HLA-DOB | More | | Lorlatinib | hsa04659 | Th17 cell differentiation | 8.36E-04 | 14 | P25963, Q04759, P19174, P06239, P42224, P14784, P13765, Q9HBE5, Q9UL17, P23771, P84022, P08238, P09693, P20963 | NFKBIA, PRKCQ, PLCG1, LCK, STAT1, IL2RB, HLA-DOB, IL21R, TBX21, GATA3, SMAD3, HSP90AB1, CD3G, CD247 | More | | Lorlatinib | hsa04660 | T cell receptor signaling pathway | 4.75E-03 | 10 | P01375, Q9UDY8, Q04759, O95267, Q08881, P20963, P09693, P01732, Q13191, P06239 | TNF, MALT1, PRKCQ, RASGRP1, ITK, CD247, CD3G, CD8A, CBLB, LCK | More | | Lorlatinib | hsa04664 | Fc epsilon RI signaling pathway | 2.60E-04 | 6 | P04141, Q9UQC2, P07948, P19174, P09917, P20292 | CSF2, GAB2, LYN, PLCG1, ALOX5, ALOX5AP | More | | Lorlatinib | hsa04668 | TNF signaling pathway | 1.26E-02 | 4 | Q12933, Q99941, P01584, O95429 | TRAF2, CREBL1, IL1B, BAG4 | More | | Lorlatinib | hsa04713 | Circadian entrainment | 2.29E-03 | 7 | P0DP23, Q13557, Q02153, P62873, P63218, P50151, Q08828 | CALM1, CAMK2D, GUCY1B3, GNB1, GNG5, GNG10, ADCY1 | More | | Lorlatinib | hsa04714 | Thermogenesis | 3.31E-02 | 4 | P51828, P62753, P12074, O15239 | ADCY7, RPS6, COX6A1, NDUFA1 | More | | Lorlatinib | hsa04720 | Long-term potentiation | 2.85E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | | Lorlatinib | hsa04724 | Glutamatergic synapse | 1.57E-02 | 4 | P62873, P63218, P50151, P15104 | GNB1, GNG5, GNG10, GLUL | More | | Lorlatinib | hsa04725 | Cholinergic synapse | 2.17E-02 | 3 | P51828, P18848, Q13557 | ADCY7, ATF4, CAMK2D | More | | Lorlatinib | hsa04726 | Serotonergic synapse | 3.80E-02 | 4 | P62873, P63218, P50151, P09917 | GNB1, GNG5, GNG10, ALOX5 | More | | Lorlatinib | hsa04727 | GABAergic synapse | 4.18E-03 | 4 | P62873, P63218, P50151, P15104 | GNB1, GNG5, GNG10, GLUL | More | | Lorlatinib | hsa04728 | Dopaminergic synapse | 4.78E-02 | 3 | Q99941, P18848, Q13557 | CREBL1, ATF4, CAMK2D | More | | Lorlatinib | hsa04730 | Long-term depression | 4.86E-02 | 2 | Q14344, P07948 | GNA13, LYN | More | | Lorlatinib | hsa04744 | Phototransduction | 9.21E-03 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Lorlatinib | hsa04750 | Inflammatory mediator regulation of TRP channels | 4.25E-02 | 3 | P01584, Q08828, Q13557 | IL1B, ADCY1, CAMK2D | More | | Lorlatinib | hsa04911 | Insulin secretion | 3.43E-05 | 5 | Q08828, P51828, Q99941, P18848, Q13557 | ADCY1, ADCY7, CREBL1, ATF4, CAMK2D | More | | Lorlatinib | hsa04912 | GnRH signaling pathway | 2.17E-02 | 3 | P51828, P18848, Q13557 | ADCY7, ATF4, CAMK2D | More | | Lorlatinib | hsa04914 | Progesterone-mediated oocyte maturation | 1.00E-02 | 4 | Q17RY0, Q9Y6D9, P51812, Q02750 | CPEB4, MAD1L1, RPS6KA3, MAP2K1 | More | | Lorlatinib | hsa04915 | Estrogen signaling pathway | 2.75E-03 | 5 | Q99941, P18848, P51828, P07900, P11142 | CREBL1, ATF4, ADCY7, HSP90AA1, HSPA8 | More | | Lorlatinib | hsa04918 | Thyroid hormone synthesis | 1.69E-03 | 4 | P51828, Q99941, P18848, P02768 | ADCY7, CREBL1, ATF4, ALB | More | | Lorlatinib | hsa04925 | Aldosterone synthesis and secretion | 1.69E-03 | 4 | Q99941, P18848, P51828, Q13557 | CREBL1, ATF4, ADCY7, CAMK2D | More | | Lorlatinib | hsa04926 | Relaxin signaling pathway | 4.13E-03 | 5 | P63218, Q99941, P18848, P51828, P30679 | GNG5, CREBL1, ATF4, ADCY7, GNA15 | More | | Lorlatinib | hsa04927 | Cortisol synthesis and secretion | 4.16E-03 | 3 | Q99941, P18848, P51828 | CREBL1, ATF4, ADCY7 | More | | Lorlatinib | hsa04928 | Parathyroid hormone synthesis, secretion and action | 2.17E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | | Lorlatinib | hsa04932 | Non-alcoholic fatty liver disease | 4.44E-02 | 4 | Q12933, P01584, P12074, O15239 | TRAF2, IL1B, COX6A1, NDUFA1 | More | | Lorlatinib | hsa04934 | Cushing syndrome | 1.98E-05 | 6 | Q99941, P18848, Q08828, P51828, O15169, Q13557 | CREBL1, ATF4, ADCY1, ADCY7, AXIN1, CAMK2D | More | | Lorlatinib | hsa04935 | Growth hormone synthesis, secretion and action | 2.72E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | | Lorlatinib | hsa04962 | Vasopressin-regulated water reabsorption | 7.22E-03 | 2 | P52566, P62491 | ARHGDIB, RAB11A | More | | Lorlatinib | hsa05010 | Alzheimer disease | 1.23E-02 | 8 | Q92542, O15239, P05496, P12074, P01584, Q12933, O15169, P43686 | NCSTN, NDUFA1, ATP5G1, COX6A1, IL1B, TRAF2, AXIN1, PSMC4 | More | | Lorlatinib | hsa05012 | Parkinson disease | 2.28E-03 | 12 | P62987, O15239, P12074, P05496, P60604, P43686, P19174, P0DP23, Q13557, Q71U36, Q13509, P68371 | UBA52, NDUFA1, COX6A1, ATP5G1, UBE2G2, PSMC4, PLCG1, CALM1, CAMK2D, TUBA1A, TUBB3, TUBB2C | More | | Lorlatinib | hsa05014 | Amyotrophic lateral sclerosis | 2.99E-02 | 7 | O15239, P12074, P05496, Q12933, P43686, P37198, P35658 | NDUFA1, COX6A1, ATP5G1, TRAF2, PSMC4, NUP62, NUP214 | More | | Lorlatinib | hsa05017 | Spinocerebellar ataxia | 2.16E-02 | 2 | Q8TB72, P21796 | PUM2, VDAC1 | More | | Lorlatinib | hsa05020 | Prion disease | 2.99E-02 | 7 | P01584, P46531, O15239, P05496, P12074, P43686, Q99941 | IL1B, NOTCH1, NDUFA1, ATP5G1, COX6A1, PSMC4, CREBL1 | More | | Lorlatinib | hsa05022 | Pathways of neurodegeneration - multiple diseases | 9.10E-03 | 9 | O15239, P12074, P05496, Q12933, O15169, P01584, Q13557, P62987, P43686 | NDUFA1, COX6A1, ATP5G1, TRAF2, AXIN1, IL1B, CAMK2D, UBA52, PSMC4 | More | | Lorlatinib | hsa05030 | Cocaine addiction | 4.87E-02 | 2 | Q99941, P18848 | CREBL1, ATF4 | More | | Lorlatinib | hsa05031 | Amphetamine addiction | 6.41E-03 | 3 | Q13557, Q99941, P18848 | CAMK2D, CREBL1, ATF4 | More | | Lorlatinib | hsa05032 | Morphine addiction | 2.18E-02 | 4 | P62873, P63218, P50151, Q13370 | GNB1, GNG5, GNG10, PDE3B | More | | Lorlatinib | hsa05034 | Alcoholism | 1.96E-04 | 6 | Q96RR4, Q93077, P62807, O60814, P84243, P68431 | CAMKK2, HIST1H2AC, HIST1H2BC, H2BC12, H3F3A, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Lorlatinib | hsa05100 | Bacterial invasion of epithelial cells | 2.85E-02 | 3 | Q14141, Q05397, Q96JJ3 | SEPT6, PTK2, ELMO2 | More | | Lorlatinib | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 1.08E-02 | 4 | P25963, Q13488, P19174, P07948 | NFKBIA, TCIRG1, PLCG1, LYN | More | | Lorlatinib | hsa05130 | Pathogenic Escherichia coli infection | 3.19E-02 | 6 | Q71U36, P16333, Q13509, P68371, Q14344, P25963 | TUBA1A, NCK1, TUBB3, TUBB2C, GNA13, NFKBIA | More | | Lorlatinib | hsa05131 | Shigellosis | 1.80E-02 | 5 | Q13546, Q9UDY8, Q12778, Q13315, P10415 | RIPK1, MALT1, FOXO1, ATM, BCL2 | More | | Lorlatinib | hsa05132 | Salmonella infection | 4.61E-05 | 12 | P25963, P08238, Q9UJU2, Q13546, Q13489, P10415, O75369, Q13561, Q71U36, Q13509, P68371, P49754 | NFKBIA, HSP90AB1, LEF1, RIPK1, BIRC3, BCL2, FLNB, DCTN2, TUBA1A, TUBB3, TUBB2C, VPS41 | More | | Lorlatinib | hsa05134 | Legionellosis | 4.75E-02 | 3 | P25963, P11215, P11142 | NFKBIA, ITGAM, HSPA8 | More | | Lorlatinib | hsa05135 | Yersinia infection | 3.29E-02 | 4 | Q05397, P51812, Q02750, Q96JJ3 | PTK2, RPS6KA3, MAP2K1, ELMO2 | More | | Lorlatinib | hsa05140 | Leishmaniasis | 4.71E-03 | 10 | P13612, O75015, P14598, P11215, P42224, P13765, O60603, P25963, P01375, Q15080 | ITGA4, FCGR3B, NCF1, ITGAM, STAT1, HLA-DOB, TLR2, NFKBIA, TNF, NCF4 | More | | Lorlatinib | hsa05144 | Malaria | 1.14E-02 | 5 | P60033, O60603, P01375, P35443, P26718 | CD81, TLR2, TNF, THBS4, KLRK1 | More | | Lorlatinib | hsa05146 | Amoebiasis | 1.95E-02 | 7 | P09341, P27930, P01375, O60603, P05089, P22694, P08311 | CXCL1, IL1R2, TNF, TLR2, ARG1, PRKACB, CTSG | More | | Lorlatinib | hsa05160 | Hepatitis C | 3.16E-02 | 4 | P52630, P60033, Q9NZJ5, P49841 | STAT2, CD81, EIF2AK3, GSK3B | More | | Lorlatinib | hsa05161 | Hepatitis B | 3.34E-02 | 3 | Q99941, P18848, P27348 | CREBL1, ATF4, YWHAQ | More | | Lorlatinib | hsa05163 | Human cytomegalovirus infection | 2.56E-03 | 8 | P25963, P62873, P63218, P50151, P0DP23, Q14344, P30101, P01568 | NFKBIA, GNB1, GNG5, GNG10, CALM1, GNA13, PDIA3, IFNA21 | More | | Lorlatinib | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 8.62E-05 | 10 | P01568, P42224, P25963, P62873, P63218, P50151, P19174, P07948, P04141, P0DP23 | IFNA21, STAT1, NFKBIA, GNB1, GNG5, GNG10, PLCG1, LYN, CSF2, CALM1 | More | | Lorlatinib | hsa05168 | Herpes simplex virus 1 infection | 3.79E-02 | 9 | P25963, P01568, P42224, Q07955, Q01130, Q13243, P30101, Q13398, O75820 | NFKBIA, IFNA21, STAT1, SFRS1, SFRS2, SFRS5, PDIA3, ZNF211, ZNF189 | More | | Lorlatinib | hsa05170 | Human immunodeficiency virus 1 infection | 1.19E-02 | 8 | P62873, P63218, P50151, P0DP23, P30101, P01568, P25963, P19174 | GNB1, GNG5, GNG10, CALM1, PDIA3, IFNA21, NFKBIA, PLCG1 | More | | Lorlatinib | hsa05200 | Pathways in cancer | 1.46E-04 | 19 | P08238, P42224, P25963, P19174, P43246, P84022, Q13485, P20585, P52701, P30279, P62873, P63218, P50151, Q14344, P78417, O75293, P0DP23, P01568, P14784 | HSP90AB1, STAT1, NFKBIA, PLCG1, MSH2, SMAD3, SMAD4, MSH3, MSH6, CCND2, GNB1, GNG5, GNG10, GNA13, GSTO1, GADD45B, CALM1, IFNA21, IL2RB | More | | Lorlatinib | hsa05202 | Transcriptional misregulation in cancer | 2.35E-02 | 12 | Q13315, P14780, P27930, Q15744, Q16548, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, P24522 | ATM, MMP9, IL1R2, CEBPE, BCL2A1, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, GADD45A | More | | Lorlatinib | hsa05203 | Viral carcinogenesis | 2.63E-03 | 7 | Q99941, P18848, P27348, Q15283, P61978, P62807, O60814 | CREBL1, ATF4, YWHAQ, RASA2, HNRPK, HIST1H2BC, H2BC12 | More | | Lorlatinib | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Lorlatinib | hsa05210 | Colorectal cancer | 4.94E-02 | 2 | Q13485, P52701 | SMAD4, MSH6 | More | | Lorlatinib | hsa05212 | Pancreatic cancer | 4.75E-02 | 3 | P42224, P84022, O75293 | STAT1, SMAD3, GADD45B | More | | Lorlatinib | hsa05214 | Glioma | 4.75E-02 | 3 | P0DP23, P19174, O75293 | CALM1, PLCG1, GADD45B | More | | Lorlatinib | hsa05215 | Prostate cancer | 3.03E-02 | 3 | P10415, Q12778, Q9NRA1 | BCL2, FOXO1, PDGFC | More | | Lorlatinib | hsa05217 | Basal cell carcinoma | 4.31E-02 | 2 | P04628, Q9UJU2 | WNT1, LEF1 | More | | Lorlatinib | hsa05310 | Asthma | 1.92E-02 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Lorlatinib | hsa05321 | Inflammatory bowel disease | 1.30E-04 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, Q9HBE5 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL21R | More | | Lorlatinib | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Lorlatinib | hsa05332 | Graft-versus-host disease | 2.17E-02 | 4 | P13765, P01375, P26715, Q13241 | HLA-DOB, TNF, KLRC1, KLRD1 | More | | |